Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Other Operating Expenses (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Other Operating Expenses for 10 consecutive years, with $1000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses fell 99.99% to $1000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $3.9 million, a 87.25% decrease, with the full-year FY2024 number at $4.5 million, changed N/A from a year prior.
  • Other Operating Expenses was $1000.0 for Q3 2025 at Theravance Biopharma, down from $3.9 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $114.4 million in Q4 2022 to a low of -$37.5 million in Q3 2022.
  • A 5-year average of $11.2 million and a median of $3.5 million in 2022 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: tumbled 175.51% in 2022, then surged 212.71% in 2023.
  • Theravance Biopharma's Other Operating Expenses stood at -$13.6 million in 2021, then skyrocketed by 939.3% to $114.4 million in 2022, then crashed by 91.76% to $9.4 million in 2023, then plummeted by 58.3% to $3.9 million in 2024, then crashed by 99.97% to $1000.0 in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Other Operating Expenses are $1000.0 (Q3 2025), $3.9 million (Q4 2024), and $10.8 million (Q3 2024).